Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells

Area of Science:

• Cardiovascular Biology
• Inflammation Research
• Molecular Medicine

Background:

• C-reactive protein (CRP) is increasingly implicated in atherogenesis.
• CRP triggers inflammatory responses in endothelial cells.
• Nuclear factor-kappaB (NF-kappaB) signaling is crucial for proatherogenic gene expression.

Purpose of the Study:

• To investigate the effects of CRP and lovastatin on NF-kappaB activation in human umbilical vein endothelial cells (HUVECs).
• To elucidate the molecular mechanisms underlying CRP-induced inflammation and lovastatin's inhibitory action.

Main Methods:

• Electrophoretic mobility shift assays (EMSA) to assess NF-kappaB activation.
• Western blotting to analyze inhibitory kappa B-alpha (IkappaB-alpha) stabilization.
• Flow cytometry to measure CD40 expression.
• Treatment with CRP, lovastatin, and NF-kappaB inhibitor pyrrolidinethiocarbamate (PDTC).

Main Results:

• CRP significantly increased NF-kappaB activation and IkappaB degradation in HUVECs.
• Lovastatin effectively diminished CRP-induced NF-kappaB activation.
• Lovastatin appeared to stabilize IkappaB-alpha, inhibiting NF-kappaB nuclear translocation.
• PDTC preincubation reduced CRP-induced CD40 expression, indicating NF-kappaB's role.

Conclusions:

• CRP activates NF-kappaB and upregulates CD40 expression in HUVECs, partly through NF-kappaB signaling.
• Lovastatin mitigates CRP-induced inflammation by inhibiting NF-kappaB activation.
• These findings highlight a potential therapeutic strategy for atherosclerosis involving statins targeting inflammatory pathways.